Mer­ck helps bankroll new part­ner Themis' game plan to fin­ish the chikun­gun­ya race and be­gin on­colyt­ic virus quest

As Themis gears up for a Phase III tri­al of its chikun­gun­ya vac­cine, the Vi­en­na-based biotech has closed out €40 mil­lion ($44 mil­lion) to foot the clin­i­cal and man­u­fac­tur­ing bills.

Its heavy­weight part­ners at Mer­ck — which signed a pact around a mys­te­ri­ous “block­buster in­di­ca­tion” last month — jumped in­to the Se­ries D, led by new in­vestors Far­al­lon Cap­i­tal and Hadean Ven­tures. Ad­ju­vant Cap­i­tal al­so joined, as did cur­rent in­vestors Glob­al Health In­vest­ment Fund, aws Gru­en­der­fonds, Omnes Cap­i­tal, Ven­tech and Welling­ton Part­ners Life Sci­ences.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER